AltruBio, Inc.

[Available On-Demand]
AltruBio is a clinical stage biopharmaceutical company with the strength in developing novel biologics for the treatment of immunological diseases with high unmet medical needs. Based on unique insights into immune tolerance and epitope dominance sciences, AltruBio's pipeline is focused on the depletion of unwanted activated T-cells with proof of mechanism in four autoimmune and inflammatory diseases.
AltruBio has the first-in-class checkpoint regulator PGSL-1 agonist antibodies which can be leveraged as the technology platform to address the needs in many immunological and inflammatory diseases.
Company Type:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Neihulizumab AbGn-168H
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
CEO and President
AltruBio, Inc.